JAMA · 2015 · 47 citations · 7 references
PharmacyPharmacologyPharmacotherapyCardiovascular PharmacotherapyClinical PharmacologyCardiovascular DiseaseCholesterol MetabolismDyslipidemia ManagementLipid ManagementLipid-lowering TherapyLipoprotein MetabolismHigh-density Lipoprotein Cholesterol ManagementHyperlipidemia TreatmentPcsk9 Inhibitor TherapyPcsk9 InhibitorsProprotein Convertase Subtilisin/kexin Type 9 InhibitionProprotein ConvertasesTreatment Targets In Dyslipidemia
This Viewpoint discusses the need to achieve consensus around management strategies for patients with hyperlipidemia when proprotein convertase subtilisin/kexin type 9 (PCSK-9) inhibitors enter the marketplace.
7
Heart disease and stroke statistics--2015 update: a report from the American Heart Association.
Dariush Mozaffarian, Emelia J. Benjamin, Alan S. Go et al. · PubMed · 2015 · 8.3K citations
Børge G. Nordestgaard, M. John Chapman, Steve E. Humphries et al. · European Heart Journal · 2013 · 2.7K citations · Full text